U.S. Markets open in 8 hrs 19 mins

Inspire Medical Systems, Inc. (INSP)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
188.29+5.19 (+2.83%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close183.10
Open185.00
Bid0.00 x 800
Ask0.00 x 1000
Day's Range184.32 - 191.22
52 Week Range82.77 - 252.25
Volume258,668
Avg. Volume229,226
Market Cap5.255B
Beta (5Y Monthly)1.63
PE Ratio (TTM)N/A
EPS (TTM)-2.19
Earnings DateAug 02, 2021 - Aug 06, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est255.60
  • Inspire Medical Systems, Inc. to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
    GlobeNewswire

    Inspire Medical Systems, Inc. to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

    MINNEAPOLIS, May 25, 2021 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will be presenting at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10, 2021. Inspire is scheduled to present at 2:10 p.m. Eastern Time. The presentation will be accessible via a live webcast at https://kvgo.com/gs-global-healthcare/inspire-medical-systems-june-2021. A webcast replay of the presentation will be available for two weeks following the presentation in the Event Archive section of Inspire’s Investor website at https://investors.inspiresleep.com. About Inspire Medical SystemsInspire is a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. For additional information about Inspire, please visit www.inspiresleep.com. Investor and Media Contact:Bob YedidLifeSci Advisorsbob@lifesciadvisors.com 646-597-6989

  • UPDATE – Inspire Medical Systems, Inc. Announces Positive Coverage Policy Issued by Anthem for Inspire Therapy
    GlobeNewswire

    UPDATE – Inspire Medical Systems, Inc. Announces Positive Coverage Policy Issued by Anthem for Inspire Therapy

    MINNEAPOLIS, May 20, 2021 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) ("Inspire"), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea (“OSA”), announced today that Anthem, Inc. (“Anthem”) will provide coverage for the Company’s Inspire therapy, effective May 20, 2021. Anthem is a leading health benefits company dedicated to improving lives and communities and making healthcare simpler that, through its affiliated companies, serves 42 million individuals within its family of health plans. “We are pleased to receive this positive coverage decision from Anthem, bringing the total to 64 commercial insurance plans, and inclusive of Medicare represents approximately 260 million lives,” said Tim Herbert, President and Chief Executive Officer of Inspire Medical Systems. “Anthem was providing approval through the prior authorization process and conducted a mid-cycle review of the Inspire technology, resulting in this positive coverage policy. This positive coverage decision provides additional OSA patients who are unable to benefit from CPAP the opportunity to gain access to Inspire therapy.” In addition to these commercial coverage policies, Inspire therapy also has Medicare coverage across the entire United States. About Inspire Medical Systems Inspire is a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. For additional information about Inspire, please visit www.inspiresleep.com. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as ‘‘may,’’ ‘‘will,’’ ‘‘should,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘anticipate,’’ ‘‘could,’’ “future,” “outlook,” “guidance,” ‘‘intend,’’ ‘‘target,’’ ‘‘project,’’ ‘‘contemplate,’’ ‘‘believe,’’ ‘‘estimate,’’ ‘‘predict,’’ ‘‘potential,’’ ‘‘continue,’’ or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements are based on management’s current expectations and involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Other important factors that could cause actual results, performance or achievements to differ materially from those contemplated in this press release can be found under the captions “Risk Factors” and "Management's Discussion and Analysis of Financial Condition and Results of Operations“ in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 filed with the SEC, and as such factors may be updated from time to time in our other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov and the Investors page of our website at www.inspiresleep.com. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, unless required by applicable law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Thus, one should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Investor & Media Contact:Bob YedidLifeSci Advisors646-597-6989Bob@LifeSciAdvisors.com

  • Inspire Medical Systems, Inc. Announces Positive Coverage Policy Issued by Anthem for Inspire Therapy
    GlobeNewswire

    Inspire Medical Systems, Inc. Announces Positive Coverage Policy Issued by Anthem for Inspire Therapy

    MINNEAPOLIS, May 20, 2021 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) ("Inspire"), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea (“OSA”), announced today that Anthem, Inc. (“Anthem”) will provide coverage for the Company’s Inspire therapy, effective May 20, 2021. Anthem is a leading health benefits company dedicated to improving lives and communities and making healthcare simpler that, through its affiliated companies, serves 42 million individuals within its family of health plans. “We are pleased to receive this positive coverage decision from Anthem, bringing the total to 64 commercial insurance plans, representing approximately 262 million members, that cover Inspire therapy,” said Tim Herbert, President and Chief Executive Officer of Inspire Medical Systems. “Anthem was providing approval through the prior authorization process and conducted a mid-cycle review of the Inspire technology, resulting in this positive coverage policy. This positive coverage decision provides additional OSA patients who are unable to benefit from CPAP the opportunity to gain access to Inspire therapy.” In addition to these commercial coverage policies, Inspire therapy also has Medicare coverage across the entire United States. About Inspire Medical Systems Inspire is a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. For additional information about Inspire, please visit www.inspiresleep.com. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as ‘‘may,’’ ‘‘will,’’ ‘‘should,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘anticipate,’’ ‘‘could,’’ “future,” “outlook,” “guidance,” ‘‘intend,’’ ‘‘target,’’ ‘‘project,’’ ‘‘contemplate,’’ ‘‘believe,’’ ‘‘estimate,’’ ‘‘predict,’’ ‘‘potential,’’ ‘‘continue,’’ or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements are based on management’s current expectations and involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Other important factors that could cause actual results, performance or achievements to differ materially from those contemplated in this press release can be found under the captions “Risk Factors” and "Management's Discussion and Analysis of Financial Condition and Results of Operations“ in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 filed with the SEC, and as such factors may be updated from time to time in our other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov and the Investors page of our website at www.inspiresleep.com. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, unless required by applicable law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Thus, one should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Investor & Media Contact:Bob YedidLifeSci Advisors646-597-6989Bob@LifeSciAdvisors.com